News
PLNT CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Planet Fitness Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Planet Fitness To Contact Him Directly To Discuss Their Options If you purchased or a
ADMA CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options If you purchased or a
PICS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds PicS N.V. (PICS) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PicS To Contact Him Directly To Discuss Their Options If you purchased or acquired Pi
Medical AI Startup OpenEvidence Weighs $200 Million Funding Round
Medical-focused artificial intelligence startup OpenEvidence has reportedly considered raising $200 million at a $20 billion valuation. However, the company is unlikely to proceed, partly because the
LCID CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Lucid Group (LCID) Investors of Securities Class Action Lawsuit Deadline on July 28, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lucid Group To Contact Him Directly To Discuss Their Options If you purchased or acqu
ERAS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Erasca To Contact Him Directly To Discuss Their Options If you purchased or acquired
VRRM CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Verra (VRRM) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Verra To Contact Him Directly To Discuss Their Options If you purchased or acquired s
BMI CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Badger Meter (BMI) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Badger Meter To Contact Him Directly To Discuss Their Options If you purchased or acq
NNOX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nano-X Imaging (NNOX) Investors of Securities Class Action Lawsuit Deadline on August 11, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nano-X To Contact Him Directly To Discuss Their Options If you purchased or acquired
VIA CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Via Transportation (VIA) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Via Transportation To Contact Him Directly To Discuss Their Options If you purchased
LUCID DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Lucid Group, Inc. Investors to Secure Counsel Before Important July 28 Deadline in Securities Class Action - LCID
NEW YORK, July 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lucid Group, Inc. (NASDAQ: LCID) between February 25, 2026 and A
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verra Mobility Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - VRRM
New York, New York--(Newsfile Corp. - July 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Verra Mobility Corporation (NASDAQ: VRRM) between F
Titan International: Industry Weakness Offsets A Cheap Valuation
Titan International remains a ‘hold' due to persistent end-market headwinds in agriculture and construction, despite its compelling valuation. Q1 2026 revenue rose to $505.1M, but losses widened to $2
China cracks down on chatbot romances as birthrate crisis worsens: report
New rules targeting AI companions reportedly seek to curb emotional dependence as China faces a shrinking population and record-low birthrate.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages GPGI, Inc. f/k/a CompoSecure, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GPGI, CMPO
NEW YORK, July 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Class A common stock of GPGI, Inc. f/k/a
ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS
NEW YORK, July 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026
Bank of America Promotes Execs to Champion AI and Crypto
Bank of America has reportedly promoted new leaders to guide its artificial intelligence and crypto efforts. Sonali Theisen has been named the bank's head of global digital-assets platform and Kevin M
TSMC is accelerating Arizona factory buildout to capitalize on AI 'megatrend,' CFO says
Speaking in an exclusive interview with CNBC, TSMC Chief Financial Officer Wendell Huang said the chipmaker will double down on its Arizona expansion. The company's 2-nanometer technology will drive i
Neuronata-R retains conditional approval in South Korea
/PRNewswire/ -- Patients with amyotrophic lateral sclerosis (ALS) in South Korea will keep their access to Neuronata-R (lenzumestrocel) - a stem cell therapy
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at
